Image
Clinical Research Updates™

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Guidelines

2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.

Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Smolen JS, et al. Ann Rheum Dis. 2013;72(4):482-492.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Smolen JS, et al. Ann Rheum Dis. 2014;73(3):492-509.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Smolen JS, et al. Ann Rheum Dis. 2016;75(1):3-15.

Patient Resources

American College of Rheumatology Disease Overview

The American College of Rheumatology has published a concise overview to help patients and caregivers learn more about rheumatoid arthritis and provide tips for living well with this rheumatic disease. 

American College of Rheumatology Patient Education Videos

The American College of Rheumatology has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with a rheumatic disease.

Handout on Health: Rheumatoid Arthritis

A publication from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease. 

Suggested Readings

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

McInnes IB, et al. Ann Rheum Dis. 2015;74(4):694-702.

IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future

Kim GW, et al. Arch Pharm Res. 2015;38(5):575-584.

IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab

Tanaka Y, Martin Mola E. Ann Rheum Dis. 2014;73(9):1595-1597.

Measures of rheumatoid arthritis disease activity

Anderson JK, et al. Arthritis Care Res (Hoboken). 2011;63(suppl 11):S14-S36.

The pathogenesis of rheumatoid arthritis

McInnes IB, Schett G. N Engl J Med. 2011;365(23):2205-2219.

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study

Genovese MC, et al. Arthritis Rheumatol. 2015;67(6):1424-1437.

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

Dennis G Jr, et al. Arthritis Res Ther. 2014;16(2):R90.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

Burmester GR, et al. Ann Rheum Dis. 2015.

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year

Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Gabay C, et al. Lancet. 2013;381(9877):1541-1550.

Interactive Presentation

IL-6 in Rheumatoid Arthritis

From Pathophysiology to Individualized Therapy


Activity
Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances